Illumina, Inc. $ILMN Shares Bought by Neuberger Berman Group LLC

Neuberger Berman Group LLC grew its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 122.1% during the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 57,187 shares of the life sciences company’s stock after purchasing an additional 31,438 shares during the period. Neuberger Berman Group LLC’s holdings in Illumina were worth $5,456,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Parkside Financial Bank & Trust boosted its holdings in Illumina by 65.7% during the second quarter. Parkside Financial Bank & Trust now owns 290 shares of the life sciences company’s stock worth $28,000 after buying an additional 115 shares in the last quarter. Rise Advisors LLC boosted its stake in shares of Illumina by 173.6% during the 1st quarter. Rise Advisors LLC now owns 353 shares of the life sciences company’s stock worth $28,000 after acquiring an additional 224 shares in the last quarter. Cullen Frost Bankers Inc. purchased a new stake in shares of Illumina during the 2nd quarter worth approximately $41,000. NewSquare Capital LLC grew its holdings in shares of Illumina by 604.9% in the 2nd quarter. NewSquare Capital LLC now owns 430 shares of the life sciences company’s stock worth $41,000 after acquiring an additional 369 shares during the period. Finally, Evelyn Partners Investment Management LLP increased its stake in Illumina by 4,927.3% in the 2nd quarter. Evelyn Partners Investment Management LLP now owns 553 shares of the life sciences company’s stock valued at $49,000 after purchasing an additional 542 shares in the last quarter. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Illumina Stock Performance

Shares of NASDAQ ILMN opened at $134.87 on Monday. The company has a 50-day simple moving average of $114.71 and a 200-day simple moving average of $102.88. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.43 and a quick ratio of 1.12. The company has a market cap of $20.61 billion, a PE ratio of 30.24, a price-to-earnings-growth ratio of 2.41 and a beta of 1.44. Illumina, Inc. has a 12 month low of $68.70 and a 12 month high of $153.06.

Illumina (NASDAQ:ILMN) last announced its earnings results on Thursday, October 30th. The life sciences company reported $1.34 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.16 by $0.18. The firm had revenue of $1.08 billion for the quarter, compared to analyst estimates of $1.07 billion. Illumina had a net margin of 16.40% and a return on equity of 29.21%. Illumina’s revenue was up .4% compared to the same quarter last year. During the same quarter last year, the business earned $1.14 earnings per share. Illumina has set its FY 2025 guidance at 4.650-4.750 EPS. On average, equities analysts anticipate that Illumina, Inc. will post 4.51 earnings per share for the current year.

Wall Street Analysts Forecast Growth

ILMN has been the topic of several research reports. Barclays reissued an “underweight” rating on shares of Illumina in a report on Monday. Zacks Research raised shares of Illumina from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, December 2nd. Evercore ISI lifted their target price on shares of Illumina from $132.00 to $142.00 and gave the stock an “outperform” rating in a research report on Friday, October 31st. Royal Bank Of Canada set a $124.00 price target on shares of Illumina in a research report on Tuesday, September 2nd. Finally, Wall Street Zen upgraded Illumina from a “hold” rating to a “buy” rating in a research report on Saturday, November 8th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, thirteen have given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $115.00.

Insider Activity at Illumina

In other Illumina news, Director Scott Gottlieb bought 500 shares of the company’s stock in a transaction that occurred on Monday, November 3rd. The stock was purchased at an average cost of $122.13 per share, for a total transaction of $61,065.00. Following the completion of the purchase, the director owned 12,523 shares of the company’s stock, valued at $1,529,433.99. This trade represents a 4.16% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 0.17% of the stock is currently owned by corporate insiders.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.